Completion of the last patient treatment in a clinical trial of a sub conjunctiva inserts to treat glaucoma

TEL AVIV (April 26, 2017) – BioLight Life Sciences Ltd. (TASE: BOLT), The Company hereby announces that on April 25, 2017, ViSci Ltd., a subsidiary of the Company, announced that the last participant in the Phase I / IIa clinical trial conducted in the United States under the Food and Drug Administration (FDA) has completed his treatment, and believes that final clinical results of the trial are expected in the second half of 2017.

The clinical trial is part of the regulatory process of VS 101, a sub conjunctiva insert for the controlled and sustained release of ophthalmic drugs for the treatment of glaucoma using latanoprost (insert), based on the Eye-D™ technology.

The purpose of the trial is to prove the safety of the insert and to determine the dosage of the drug suitable for the treatment. The use of the insert might provide a solution to the current major problem of compliance of patients with glaucoma to eye drop treatments.